Loading...

NBY NOVABAY PHARMACEUTICALS INC Disposals and divestitures 8-K Filing

NVBY

NBY

NOVABAY PHARMACEUTICALS INC

(NBY)

2024 8-K

Stock Preferences Update

Compliance Regained

Major Stock Changes

CEO Resignation

Special Dividend Announcement

Special Cash Dividend

Investment Agreement

Company Liquidation

Settlement Agreements

Advisory Agreement

Asset Sale Update

CEO Contract Extension

Special Meeting Update

Special Meeting Results

Asset Sale Update

Asset Sale Update

Asset Sale Announcement

Asset Sale Agreement

Public Offering

Earnings Report

Warrant Reprice Transactions

Reverse Stock Split

Sale of Subsidiary

Delisting Notice

Update Presentation

Delisting Notice

Completion of Asset Sale

Entry into a Material Defin...

License Agreement with Sono...

Warrant Reprice Transactions

Management Extension

Amendment to Bylaws and Ann...

Private Placement

Private Placement

Resignation and Appointment

External Links:

NovaBay Pharmaceuticals is considering terminating an asset sale agreement for its Avenova brand eyecare products after receiving a superior unsolicited offer of $11.5 million from Refresh Acquisitions, compared to the previous offer of $9.5 million from PRN Physician Recommended Nutriceuticals.

AI Assistant

NOVABAY PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.